Latest news

• The year of the blockbuster

  Biktarvy (tenofovir alafenamide emtricitabine bictegravir) from Gilead:Gilead’s HIV triplet comprising the nucleoside reverse transcriptase inhibitor tenofovir alafenamide, the nucleoside reverse transcriptase inhibitor emtricitabine and the novel

• Daily Brief: AI to boost early NHS cancer diagnosis, AZ shareholder revolt, Juluca approval

  However Gilead has its own direct competitor, Biktarvy combines the novel integrase inhibitor bictegravir with Gilead's Descovy, a combo of emtricitabine and tenofovir alafenamide.

• CHMP backs first-line use for AZ’s Tagrisso in lung cancer

  There was also good news at the CHMP meeting for Gilead Sciences’HIV division, with the panel giving its blessing to three-drug, fixed-dose therapy Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide).

• Morning brief: Allergan’s migraine results, Biktarvy approved in Europe and more

  Gilead’s HIV drug Biktarvy recommended in Europe. On Friday Europe’s CHMP recommended a marketing authorisation for Gilead’s new HIV treatment Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide).

• ViiV’s two-drug HIV combo backed by CHMP

  Its main rival is expected to be Gilead’s new fixed-dose regimen Biktarvy, which combines integrase inhibitor bictegravir with the two ingredients in its fast-growing Descovy (emtricitabine/tenofovir alafenamide)